

IN THE CLAIMS:

1. (Canceled).
2. (Currently Amended) A composition comprising the an amorphous compound ~~according to claim 1~~ 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine having no diffraction peak in a powder X-ray diffraction pattern and a solubility of 15 to 20 µg/mL in a 1 wt % methylcellulose solution at 37°C and methylcellulose and/or hydroxypropylmethylcellulose .
3. (Previously presented) The composition according to claim 2, wherein the mixing ratio of the amorphous compound of 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine to the total amount of methylcellulose and/or hydroxypropylmethylcellulose is in the range of 1:0.01 to 2.
4. (Canceled).
5. (Previously presented) A composition comprising the amorphous compound according to claim 1 and a polymer compound, wherein the polymer compound is one or at least two compounds selected from the group consisting of ethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylcellulose, carboxymethylethylcellulose, polyvinyl pyrrolidone, polyvinyl acetal diethylaminoacetate, methacrylic acid copolymer L, aminoalkyl methacryl acrylate copolymer E, and vinyl acetate-vinylpyrrolidone copolymer.
6. (Original) A process for producing the amorphous compound according to claim 1, said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy -2-methylpropyl)-7,8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c]- [1]benzazepine in methylene chloride to prepare a solution; and then spray-drying the solution.

7. **(Previously presented)** A process for producing the composition according to claim 2, said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and methylcellulose and/or hydroxypropylmethylcellulose in methylene chloride to prepare a solution; and then spray-drying the solution.

8. **(Previously presented)** A process for producing the composition according to claim 5, said process comprising the steps of: dissolving 2-(1-isopropoxycarbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine and the polymer compound in methylene chloride or a methylene chloride/lower alcohol mixed solvent to prepare a solution; and then spray-drying the solution.

9. **(Original)** The process according to claim 8, wherein the lower alcohol is an alkyl alcohol having 1 to 3 carbon atoms.

Claims 10-11. **(Canceled).**

12. **(Currently Amended)** A method for treating an allergic disease, wherein said method comprises the step of administering the amorphous compound according to claim 1 to an animal ~~including a human~~.

13. **(Canceled).**

14. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 2 and a pharmaceutically acceptable carrier.

15. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 3 and a pharmaceutically acceptable carrier.

16. **(Previously presented)** A pharmaceutical composition for oral administration, comprising the composition according to claim 5 and a pharmaceutically acceptable carrier.

17. **(Currently Amended)** A method for treating an allergic disease, wherein said method comprises the step of administering the composition according to claim 2 to an animal ~~including a human~~.

18. **(Currently Amended)** A method for treating an allergic disease, wherein said method comprises the step of administering the composition according to claim 3 to an animal ~~including a human~~.

19. **(Currently Amended)** A method for treating an allergic disease, wherein said method comprises the step of administering the composition according to claim 5 to an animal ~~including a human~~.

20. **(Currently Amended)** An amorphous compound of 2-(1-isopropoxy-carbonyloxy-2-methylpropyl)-7, 8-dimethoxy-4(5H), 10-dioxo-2H-1,2,3-triazolo[4,5-c][1]benzazepine having no diffraction peak in a powder X-ray diffraction pattern and a solubility of 15 to 20 µg/mL in a 1 wt % methylcellulose solution at 37°C, wherein said compound is ~~suitable for use in a pharmaceutical composition~~ produced by the process of any one of claims 6-9.

21. **(Canceled)**.

22. **(New)** The method of any one of claims 17-19 wherein said animal is a human.